Results from an Ongoing Phase I Trial in Relapsed/Refractory B-Cell ALL and the Phase II BLAST Trial of Blinatumomab in B-Precursor ALL


Results from an Ongoing Phase I Trial in Relapsed/Refractory B-Cell ALL and the Phase II BLAST Trial of Blinatumomab in B-Precursor ALL
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)
Park JH et al. CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. Proc ASH 2014;Abstract 382.

Goekbuget N et al. BLAST: A confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Proc ASH 2014;Abstract 379.

Dr Sekeres is Professor of Medicine and Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.